Back to news

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

Business Wire•16/11/2026•09:04 ET
0

Key Highlights

  • ➤KYORIN receives exclusive Japan distribution rights for DAYBUE STIX
  • ➤Acadia receives $30 million upfront payment from KYORIN
  • ➤Acadia eligible for regulatory and sales milestones plus Japanese net-sales share
  • ➤KYORIN will lead Japanese commercialization and related regulatory activities
  • ➤Japan Phase 3 trofinetide results consistent with pivotal LAVENDER study

Expert Statements

Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals

“KYORIN’s commercial expertise and established presence in Japan make them an ideal partner to bring DAYBUE to patients and families living with Rett syndrome.”

Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals

“Building on our recent launch in Europe, this agreement is an important step in our commitment to expanding access to DAYBUE for patients around the world.”

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE(®) STIX (trofinetide) in Japan

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE(®) STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in